Presidents

Paul Bowness (UK)    paul.bowness@imm.ox.ac.uk
Robert Inman (Canada)    robert.inman@uhn.ca

Local Organising Committee

Dirk Elewaut (Belgium)    dirk.elewaut@ugent.be
Filip Van den Bosch (Belgium)    filip.vandenbosch@ugent.be

Honorary Chair

Herman Mielants (Belgium)    herman.mielants@ugent.be

Scientific Committee

Jürgen Braun (Germany)
Maxime Breban (France)
Matthew Brown (Australia)
Robert Colbert (USA)
Dirk Elewaut (Belgium)
J.S. Hill Gaston (UK)
Muhammad Asim Khan (USA)
Robert Landewé (The Netherlands)
Marjatta Leirisalo-Repo (Finland)
Jose A. Lopez de Castro (Spain)
Rik Lories (Belgium)
Walter Maksymowych (Canada)
Helena Marzo-Ortega (UK)
Roger Sturrock (UK)
John Reveille (USA)
Martin Rudwaleit (Germany)
Georg Schett (Germany)
Jochen Sieper (Germany)
Filip Van den Bosch (Belgium)
Désirée van der Heijde (The Netherlands)
Rubén Burgos Vargas (Mexico)

Invited Speakers and Chairs

All Speakers and Chairs are invited by the Presidents and the Local Organising Committee.

Welcome Address

Welcome to the Eighth International Congress on Spondyloarthritis and to the city of Gent!

The field of SpA research has seen huge advances on many fronts since the inaugural Congress: the themes in the 1998 program would be notable for the absence of biologic therapy, quantitative MRI, and the biology of ERAP1.

Over the ensuing years, the Congress has become the premier international research meeting focussing on SpA. The Eighth International Congress on Spondyloarthritis will continue this strong tradition by convening a broad range of researchers spanning molecular biology and cellular immunology, genetics, epidemiology, and clinical research including imaging and clinical outcomes. The success of the meeting has been attributed to the high calibre of the research, a format which involves multidisciplinary expertise, and a venue which encourages both social and scientific interactions.

The program for the meeting showcases advances in genetics, immunology, bone biology, and inflammation in the gut and skin, as well as bone and joint. These major themes will be presented in a series of state-of-the-art lectures by international experts in the respective fields. Recognizing the high calibre of the abstracts submitted to this meeting in the past, the program this year will include more time dedicated to podium presentations of abstracts of exceptional quality. It is the goal of the meeting not only to contribute to disseminating these recent advances, but also to contribute to advancing the field of SpA research through communication and collaboration. This Congress has proved to be an ideal forum to build those synergies.

As Co-Presidents of the 2012 Congress, we extend a warm welcome to this exciting congress and to the warmth and charm of the host city of Gent.

Paul Bowness and Robert Inman,
Presidents,
8th International Congress on Spondyloarthritis
Thursday, October 4

OPENING KEYNOTE LECTURES
Chairs: Rob Inman (Canada) & Paul Bowness (UK)

16.15 Welcome
16.30 INV1 Osteoimmunology: How does the immune system communicate with the skeleton? Hiroshi Takayanagi (Tokyo, Japan)
17.15 INV2 The future - small molecule inhibitors of inflammatory rheumatic diseases? Peter Taylor (Oxford, UK)

SESSION 1 Challenges in Axial SpA - Sponsored by Abbott
Chairs: Dirk Elewaut & Filip Van den Bosch (Belgium)

18.00 Axial SpA, concept and diagnosis Désirée van der Heijde [Meersen, The Netherlands]
18.30 Treatment challenges in axial SpA Jochen Sieper [Berlin, Germany]
19.00 Opening Reception & Walking Dinner (Kapittelzaal, ground floor)

The scientific programme takes place in the Refter (ground floor) and is transmitted by a video link to the Vermeylen Room (2nd floor) as well. When the Refter is full, participants are kindly requested to follow the scientific programme in the Vermeylen Room.


HUMIRA is the only treatment proven to fight both severe non-radiographic Axial SpA and severe active ankylosing spondylitis by helping patients achieve significant improvements in signs and symptoms, disease activity, and quality of life measures1,2

*Ankylosing spondylitis (AS): Humira is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy.

*Axial spondyloarthritis without radiographic evidence of AS: Humira is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of AS but with objective signs of inflammation by MRI and/or elevated CRP, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs.

ABELITY-1 study design: 12-week double-blind, randomised, placebo-controlled study. 192 adults with active axial SpA not fulfilling the modified New York criteria for AS, who had had inadequate response or intolerance to ≥1 NSAIDs were randomised to HUMIRA 40 mg EOW (n=91) or placebo (n=94) for 12 weeks. The 12-week double-blind, placebo-controlled period will be followed by an additional 144-week open-label extension. The primary endpoint was the proportion of subjects achieving ASAS40 response at Week 12.
NAME OF THE MEDICINAL PRODUCT: Humira 40 mg solution for injection in pre-filled syringe 40 mg solution for injection in pre-filled pen.

QUALITATIVE AND QUANTITATIVE COMPOSITION: Each 0.8 ml single dose pre-filled pen contains 40 mg of adalimumab. Each 0.8 ml single dose pre-filled pen contains 40 mg of adalimumab. Adalimumab is a recombinant human monoclonal antibody expressed in Escherichia coli. The recommended dose of Humira is 40 mg every other week via subcutaneous injection. Humira should be continued during treatment with Humira. Methotrexate should be continued during treatment with Humira. Methotrexate should be continued during treatment with Humira. Methotrexate should be continued during treatment with Humira. Methotrexate should be continued during treatment with Humira.

POSOLOGY AND METHOD OF ADMINISTRATION: Humira is indicated for the treatment of moderate to severe, active rheumatoid arthritis in adult patients who have had an inadequate response to or intolerance to nonsteroidal anti-inflammatory drugs (NSAIDs), or who are intolerant to or have medical contraindications for such therapies. Information on investigations*.

UNDESIRABLE EFFECTS: Very common: Respiratory infections (including lower and upper respiratory tract infections). Rare: Acute respiratory distress syndrome, pulmonary edema, severe respiratory tract infections, pneumonia.

PHARMACEUTICAL FORM: Clear solution for injection in pre-filled syringe/Humira 40 mg solution for injection in pre-filled syringe.

NAME OF THE MEDICINAL PRODUCT: Humira 40 mg solution for injection in pre-filled syringe 40 mg solution for injection in pre-filled pen.

QUALITATIVE AND QUANTITATIVE COMPOSITION: Each 0.8 ml single dose pre-filled pen contains 40 mg of adalimumab. Each 0.8 ml single dose pre-filled pen contains 40 mg of adalimumab. Adalimumab is a recombinant human monoclonal antibody expressed in Escherichia coli. The recommended dose of Humira is 40 mg every other week via subcutaneous injection. Humira should be continued during treatment with Humira. Methotrexate should be continued during treatment with Humira. Methotrexate should be continued during treatment with Humira. Methotrexate should be continued during treatment with Humira. Methotrexate should be continued during treatment with Humira.

POSOLOGY AND METHOD OF ADMINISTRATION: Humira is indicated for the treatment of moderate to severe, active rheumatoid arthritis in adult patients who have had an inadequate response to or intolerance to nonsteroidal anti-inflammatory drugs (NSAIDs), or who are intolerant to or have medical contraindications for such therapies. Information on investigations*.

UNDESIRABLE EFFECTS: Very common: Respiratory infections (including lower and upper respiratory tract infections). Rare: Acute respiratory distress syndrome, pulmonary edema, severe respiratory tract infections, pneumonia.

PHARMACEUTICAL FORM: Clear solution for injection in pre-filled syringe/Humira 40 mg solution for injection in pre-filled syringe.

NAME OF THE MEDICINAL PRODUCT: Humira 40 mg solution for injection in pre-filled syringe 40 mg solution for injection in pre-filled pen.

QUALITATIVE AND QUANTITATIVE COMPOSITION: Each 0.8 ml single dose pre-filled pen contains 40 mg of adalimumab. Each 0.8 ml single dose pre-filled pen contains 40 mg of adalimumab. Adalimumab is a recombinant human monoclonal antibody expressed in Escherichia coli. The recommended dose of Humira is 40 mg every other week via subcutaneous injection. Humira should be continued during treatment with Humira. Methotrexate should be continued during treatment with Humira. Methotrexate should be continued during treatment with Humira. Methotrexate should be continued during treatment with Humira. Methotrexate should be continued during treatment with Humira.

POSOLOGY AND METHOD OF ADMINISTRATION: Humira is indicated for the treatment of moderate to severe, active rheumatoid arthritis in adult patients who have had an inadequate response to or intolerance to nonsteroidal anti-inflammatory drugs (NSAIDs), or who are intolerant to or have medical contraindications for such therapies. Information on investigations*.

UNDESIRABLE EFFECTS: Very common: Respiratory infections (including lower and upper respiratory tract infections). Rare: Acute respiratory distress syndrome, pulmonary edema, severe respiratory tract infections, pneumonia.

PHARMACEUTICAL FORM: Clear solution for injection in pre-filled syringe/Humira 40 mg solution for injection in pre-filled syringe.

NAME OF THE MEDICINAL PRODUCT: Humira 40 mg solution for injection in pre-filled syringe 40 mg solution for injection in pre-filled pen.

QUALITATIVE AND QUANTITATIVE COMPOSITION: Each 0.8 ml single dose pre-filled pen contains 40 mg of adalimumab. Each 0.8 ml single dose pre-filled pen contains 40 mg of adalimumab. Adalimumab is a recombinant human monoclonal antibody expressed in Escherichia coli. The recommended dose of Humira is 40 mg every other week via subcutaneous injection. Humira should be continued during treatment with Humira. Methotrexate should be continued during treatment with Humira. Methotrexate should be continued during treatment with Humira. Methotrexate should be continued during treatment with Humira. Methotrexate should be continued during treatment with Humira.

POSOLOGY AND METHOD OF ADMINISTRATION: Humira is indicated for the treatment of moderate to severe, active rheumatoid arthritis in adult patients who have had an inadequate response to or intolerance to nonsteroidal anti-inflammatory drugs (NSAIDs), or who are intolerant to or have medical contraindications for such therapies. Information on investigations*.

UNDESIRABLE EFFECTS: Very common: Respiratory infections (including lower and upper respiratory tract infections). Rare: Acute respiratory distress syndrome, pulmonary edema, severe respiratory tract infections, pneumonia.

PHARMACEUTICAL FORM: Clear solution for injection in pre-filled syringe/Humira 40 mg solution for injection in pre-filled syringe.
SESSION 2
Genetics of SpA
Chairs: Maxime Breban (France) & Stefan Siebert (UK)

08.30 INV3 Advances in the genetics of AS
Matthew Brown [Brisbane, Australia]

09.00 INV4 Advances in the genetics of PsA
Proton Rahman [Newfoundland, Canada]

09.30 O1a Dense genotyping of candidate genes identifies 16 new susceptibility loci in ankylosing spondylitis
A. Cortes, P.C. Robinson, J. Hadler, P. Leo, D.M. Evans., M.A. Brown [Australia and UK]

01b Ankylosing spondylitis is associated with SNPs in loci implicating four aminopeptidases
P.C. Robinson, A. Cortes, P. Leo, D.M. Evans, M.A. Brown [Australia and UK]

09.45 O2 Transcriptional analysis of derived dendritic cells (MD-DCs) reveals several genes differentially regulated between ankylosing spondylitis (AS) patients and healthy controls

10.00 Poster Viewing 1 (P1 - P36) and Coffee (Marquee, ground floor)

The scientific programme takes place in the Refter (ground floor) and is transmitted by a video link to the Vermeylen Room (2nd floor) as well. When the Refter is full, participants are kindly requested to follow the scientific programme in the Vermeylen Room.

SESSION 3
Pathogenesis of SpA
Chairs: Hill Gaston (UK) & Jose Lopez de Castro (Spain)

10.45 INV5 Cellular immunology of SpA
Dominique Baeten [Amsterdam, The Netherlands]

11.15 INV6 Biology of B27
Robert Colbert [Bethesda, USA]

11.45 O3 HLA-B27 dimers are targeted for degradation by an endoplasmic reticulum stress induced degradation pathway - A potential novel therapeutic target?

12.00 O4 Endoplasmic reticulum aminopeptidase-1 (ERAP1) plays a critical role in peptide binding and antigen presentation by HLA-B27
L. Chen, R. Fisher, S. Kollnberger, B. Kessler, P. Bowness [UK]

12.15 Lunch (Kapittelzaal & Marquee, ground floor)

SESSION 4
Gastrointestinal Inflammation and SpA
Chairs: Filip Van den Bosch (Belgium) & Robert Colbert (USA)

13.15 INV7 Gut microbiome and immunity
Charles Elson III [Birmingham, USA]

13.45 INV8 Gut inflammation in SpA
Dirk Elewaut [Gent, Belgium]

14.15 O5 IL-23 induces spondyloarthropathy by acting on RORGT+, CD3+, CD4+CD8 double negative enthesal resident cells
**Friday, October 5**

**SESSION 5**
Biologics in SpA: State of the Art and Future Therapies  
Chairs: Rubén Burgos Vargas (Mexico) & Robert Landewé (The Netherlands)

14.30  INV9  
Biologics in SpA: Success, challenges  
Jochen Sieper (Berlin, Germany)

15.00  INV10  
Biologics in SpA: Future directions  
Iain McInnes (Glasgow, Scotland)

15.30  Poster Viewing 2 (P37 - P71) and Coffee (Marquee, ground floor)

**SESSION 6**
Imaging of SpA  
Chairs: Helena Marzo-Ortega (UK) & Jürgen Braun (Germany)

16.15  INV11  
Advances in SpA imaging  
Mikkel Østergaard (Copenhagen, Denmark)

16.35  INV12  
Challenges in imaging-clinical correlations  
Walter Maksymowych (Alberta, Canada)

17.00  O6  
The effect of anti-tumor necrosis factor therapy with golimumab on radiographic progression in definite ankylosing spondylitis: 4-year results  
(Germany, The Netherlands, USA and Canada)

17.15  INV13  
Microanatomy of enthesitis in AS and PsA  
Dennis McGonagle (Leeds, UK)

17.45  Conclusion

20.00  Gala Dinner at the Opera House  
(Pre-registration and separate payment required)

**Saturday, October 6**

**SESSION 7**
Bone Remodelling in SpA  
Chairs: Rik Lories & Dirk Elewaut (Belgium)

08.30  INV14  
Bone homeostasis  
Steven Goldring (New York, USA)

09.00  INV15  
Bone turnover and inflammation  
Georg Schett (Erlangen, Germany)

09.30  07  
Elevated levels of WNT3a and low levels of Dickkopf-1 in serum are associated with syndesmophyte formation in ankylosing spondylitis  
E. Klingberg, M. Nurkkala, H. Carlsten, H. Forsblad-d’Elia (Sweden)

09.45  08  
Biomechanical stress as a trigger for enthesitis and new bone formation in spondyloarthritis  
P. Jacques, S. Lambrecht, E. Verheugen, C. Van Hove, E. Pauwels, R.J. Lories, G. Kollias, G. Verbruggen, D. Elewaut (Belgium and Greece)

10.00  Poster Viewing 3 (P72 - P106) and Coffee (Marquee, ground floor)

**SESSION 8**
Selected Short Oral Abstract Summaries  
Chairs: Walter Maksymowych (Canada) & Jochen Sieper (Germany)

10.45  SO1  
Expression of HLA-B27 causes loss of migratory dendritic cells in a rat model of spondyloarthritis  
L. Utriainen, D. Firmin, P. Wright, V. Cerovic, M. Breban, I.B. McInnes, S. Milling (UK and France)

10.51  SO2  
Functional interaction between the ankylosing spondylitis associated ERAP1 polymorphism and HLA-B27 in vivo  

10.57  SO3  
Endoplasmic reticulum aminopeptidase 1 interaction with HLA B27 influences the unfolded protein response  
N. Haroon, A. Lin, A. Akram, R.D. Inman (Canada)
AT MSD in Belgium and Luxemburg, we work hard to keep the world well. How? By providing people with innovative prescription medicines. We also provide leading healthcare solutions that make a difference. And we do it by listening to patients, physicians and our other partners — and anticipating their needs. You can learn more about our medicines and services on www.msd-belgium.be.

**HUMANCARE**

We believe our responsibility includes making sure that our products reach people who need them. So we’ve created many far-reaching programs and partnerships to accomplish this.

We continue on our journey to redefine ourselves to bring more hope to more people around the world. Our goals are clear and our commitment is fierce. We are dedicated to solving problems and pursuing new answers.

**Saturday, October 6**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>11.09</td>
<td>S05</td>
<td>Autoantibodies against class II-associated invariant chain peptide (CLIP) in spondyloarthritis</td>
<td>N.T. Baerlecken, S. Nothdorft, G.H. Stummvoll, J. Sieper, M. Rudwaleit, S. Reuter, T. Matthias, R.E. Schmidt, T. Witte (Germany and Austria)</td>
</tr>
</tbody>
</table>

**SESSION 9**

Earlier Diagnoses, Improved Outcomes - Sponsored by MSD

Chairs: Martin Rudwaleit (Germany) & Irene van der Horst (The Netherlands)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>11.30</td>
<td>S07</td>
<td>Referral strategies and earlier diagnosis</td>
<td>Filip Van den Bosch (Gent, Belgium)</td>
</tr>
<tr>
<td>12.00</td>
<td>S08</td>
<td>Can we halt structural progression in AS?</td>
<td>Jürgen Braun (Herne, Germany)</td>
</tr>
<tr>
<td>12.30</td>
<td>S09</td>
<td>Lunch (Kapittelzaal &amp; Marquee, ground floor)</td>
<td></td>
</tr>
</tbody>
</table>
**Saturday, October 6**

**SESSION 10**
Selected Short Oral Abstract Summaries
Chairs: Désirée van der Heijde (The Netherlands) & John Reveille (USA)

13.30 S07  The effect of biological therapy on work participation in ankylosing spondylitis patients: A systematic review
L.R.A. Van der Burg, M.M. Ter Wee, A. Boonen (The Netherlands)

13.36 S08  Brain MRI and psychophysics analysis demonstrate neuropathic pain to be a component of back pain in ankylosing spondylitis
Q. Wu, R.D. Inman, K.D. Davis (Canada)

13.42 S09  Efficacy and safety of adalimumab in peripheral spondylarthritis patients: Results from ABILITY-2
P. Mease, J. Sieper, F. Van den Bosch, P. Rahman, K. Obermeyer, A.L. Pangan (USA, Germany, Belgium and Canada)

13.48 S010 Simultaneously modelling health impact, budget impact and cost-effectiveness in the context of population dynamics: The case of tumour necrosis factor-alpha antagonist for ankylosing spondylitis in the Dutch society
A. Tran-Duy, A. Boonen, M.A.F.J. van de Laar, J.L. Severens (The Netherlands)

13.56 S011 MRI inflammation and its relation with measures of clinical disease activity and different treatment responses in patients with ankylosing spondylitis treated with a TNF inhibitor
P. Machado, R. Landewé, J. Braun, X. Baraliakos, K.G.A. Hermann, B. Hsu, D. Baker, D. van der Heijde (The Netherlands, Portugal and USA)

14.02 S012  Secukinumab significantly improves ASAS20 responses versus placebo in moderate-to-severe ankylosing spondylitis patients

**SESSION 11**
Epidemiology, Cohorts and Biomarkers AS
Chairs: Muhammad Asim Khan (USA) & Marjatta Leirisalo-Repo (Finland)

14.15 INV16  Epidemiology of SpA
John Reveille (Houston, USA)

14.40 INV17  Early cohorts
Martin Rudwaleit (Berlin, Germany)

15.05 09  Structural progression of ankylosing spondylitis associated with elevation in two novel, inflammatory biomarkers; matrix metalloproteinase and cathepsin-derived CRP
A.C. Bay-Jensen, M.A. Karsdal, D.J. Leeming, S. Wichuk, P. Qvist, W.P. Maksymowycz (Denmark and Canada)

15.18 010  Syndesmophytes are associated with higher bone turnover in ankylosing spondylitis patients with active disease
S. Arends, E. van der Veer, P.M. Houtman, M.K. Leijisma, C.G.M. Kallenberg, E. Brouwer, A. Spoorenberg (The Netherlands)

15.30 Poster Viewing 4 (S01 - S012 & P107 - P129) and Coffee (Marquee, ground floor)

**SESSION 12**
Biologics: Mechanisms for Long-Term Treatment Success - Sponsored by Pfizer
Chairs: Rob Inman (Canada) & Paul Bowness (UK)

16.15 Understanding immunogenicity and exploring clinical implications
Gertjan Wolbink (Amsterdam, The Netherlands)

16.40 Real-life data from the European biologics registries
Tore Kvien (Oslo, Norway)

17.05 Q&A

17.15 Farewell Reception and Walking Dinner (Kapittelzaal, ground floor)
Neutralizing Antibodies (NABs)

The ENBREL way in AS
Poster Viewing 1 is scheduled during the coffee break of 10.00 – 10.45 hrs on Friday, October 5. The presenters of posters P1 through P36 are requested to be present at their posters.

P1  Relative overexpression of transmembrane versus soluble TNF in spondyloarthritis

P2  Innate immune stimulation triggers experimental spondyloarthritis in HLA-B27/human beta 2 microglobulin transgenic rats
L.M. Van Duivenvoorde, G. Slobodin, N. Satumtira, M. Dorris, P.P. Tak, D.L. Baeten, J.D. Taurog (The Netherlands and USA)

P3  A reverse interferon-γ signature is shared by CD103+CD4+ dendritic cells from HLA-B27 transgenic rat and macrophages from ankylosing spondylitis patients

P4  WNT signalling inhibition as a potential therapeutic in ankylosing spondylitis

P5  Bone microarchitecture in ankylosing spondylitis in relation to lumbar osteoporosis, vertebral fractures and syndesmophyte formation

P6  DKK1 serum level is increased in recent spondyloarthritis and is associated with higher prevalence of syndesmophytes - Data from the desir cohort

P7  Effects of HLA-B27 expression on osteoclasts and osteoblasts
G. Layh-Schmitt, E. Yang, R.A. Colbert (USA)

P8  Correlation between disease activity, functional capacity, and health-related quality of life of Filipinos with ankylosing spondylitis (preliminary results)
M.G. Yu, J.H. Tan-Mangubat, E. Gonzales-Penserga (Philippines)

P9  Thyroid dysfunction is marked in patients with psoriatic arthritis (PsA)
M.H. Favarato, M.K. Schmitz, R.B. Tomita, C.G. Saad, C. Gonçalves, P. Sampaio-Barros, C. Goldenstein-Scheinberg (Brazil)

P10  How useful is imaging of the SI-joints (MRI and/or X-ray) in patients with possible spondyloarthritis in the diagnostic work-up?
R. van den Berg, M. de Hooge, V. Navarro-Compán, F. van Gaalen, M. Reijnierse, T. Huizinga, D. van der Heijde (The Netherlands)

P11  Patients fulfilling the imaging-arm and patients fulfilling the HLA-B27-arm of the ASAS axial spondyloarthritis classification criteria: Are they similar?
R. van den Berg, M. de Hooge, F. van Gaalen, M. Reijnierse, T. Huizinga, D. van der Heijde (The Netherlands)

P12  Is it useful to repeat MRI in the diagnostic work-up for spondyloarthritis?
R. van den Berg, M. de Hooge, V. Navarro-Compán, F. van Gaalen, M. Reijnierse, T. Huizinga, D. van der Heijde (The Netherlands)

P13  Almost 40% of patients with chronic back pain starting before the age of 45 fulfill the ASAS axial spondyloarthritis criteria
M. de Hooge, R. van den Berg, F. van Gaalen, M. Reijnierse, T. Huizinga, D. van der Heijde (The Netherlands)

P14  High prevalence of anti-CD 74 antibodies with specificity for the class II-associated invariant chain peptide (CLIP) in axial spondyloarthritis but not in controls
X. Baraliakos, N. Baerlecken, F. Heldmann, T. Witte, J. Braun (Germany)

P15  Secondary amyloidosis in ankylosing spondylitis and the role of anti-TNF therapy
S. Dönmez, O.N. Pamuk, G.E. Pamuk, E. Aydogdu, R. Inman (Turkey and Canada)

P16  Spinal measurements to monitor disease progression and the effects of anti-TNF therapy in ankylosing spondylitis
A.P. Corley, J. Isaacson, J.S.H. Gaston (UK)

P17  Role of 25 hiroxi-vitamin D levels in ankylosing spondylitis activity and disability
R. Aguiar, C. Ambrósio, I. Cunha, A. Barcelos (Portugal)
<table>
<thead>
<tr>
<th>Poster Viewing 1</th>
<th>Poster Viewing 1</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>P18</strong></td>
<td><strong>P28</strong></td>
</tr>
<tr>
<td>The paradoxical effects of TNF inhibitors on bone mineral density and radiographic progression in patients with ankylosing spondylitis</td>
<td>Spinal mobility measures are dependent on age – The mobility study</td>
</tr>
<tr>
<td>K.Y. Kang, I.J. Kim, J.H. Ju (South Korea and USA)</td>
<td>S. Ramiro, C. Stolwijk, A. van Tubergen, D. van der Heijde, R. Landewé (The Netherlands)</td>
</tr>
<tr>
<td><strong>P19</strong></td>
<td><strong>P29</strong></td>
</tr>
<tr>
<td>Development of a health index for patients with ankylosing spondylitis - First steps of a global initiative based on the ICF guided by ASAS</td>
<td>Disease characteristics of Filipino patients with ankylosing spondylitis in rheumatology clinics</td>
</tr>
<tr>
<td><strong>P20</strong></td>
<td><strong>P30</strong></td>
</tr>
<tr>
<td>Disease activity and new bone formation both contribute to functional impairment in ankylosing spondylitis patients</td>
<td>Intermalleolar distance and internal hip rotation are dependent on height</td>
</tr>
<tr>
<td>R. Aguiar, C. Ambrósio, I. Cunha, A. Barcelo (Portugal)</td>
<td>C. Stolwijk, S. Ramiro, R. Landewé, D. van der Heijde, A. van Tubergen (The Netherlands)</td>
</tr>
<tr>
<td><strong>P21</strong></td>
<td><strong>P31</strong></td>
</tr>
<tr>
<td>Oral contraceptive pill (OCP) use is associated with earlier onset of disease in women with ankylosing spondylitis</td>
<td>Validation of the self-administered comorbidity questionnaire in patients with ankylosing spondylitis</td>
</tr>
<tr>
<td><strong>P22</strong></td>
<td><strong>P32</strong></td>
</tr>
<tr>
<td>Diagnostic value of high sensitivity C-reactive protein (hsCRP) for early axial spondyloarthritis (SpA): Results from the desir cohort</td>
<td>Achieving ASDAS-CRP major improvement and inactive disease in patients with ankylosing spondylitis after treatment with golimumab is associated with normalized health related quality of life: Two-year results from the GO-RAISE trial</td>
</tr>
<tr>
<td>V. Navarro-Compán, D. van der Heijde, B. Combe, C. Cosson, F. van Gaalen (The Netherlands and France)</td>
<td>D. van der Heijde, A. Deodhar, J. Braun, M. Mack, B. Hsu, T. Gathany, C. Han, R.D. Inman (The Netherlands, USA, Germany and Canada)</td>
</tr>
<tr>
<td><strong>P23</strong></td>
<td><strong>P33</strong></td>
</tr>
<tr>
<td>Relationship between disease duration and treatment response in patients with ankylosing spondylitis</td>
<td>The heart in ankylosing spondylitis study (HAS study)</td>
</tr>
<tr>
<td><strong>P24</strong></td>
<td><strong>P34</strong></td>
</tr>
<tr>
<td>How frequent is family history in spondylarthitis</td>
<td>Traditional risk factors for subclinical atherosclerosis can not explain the higher prevalence of cardiovascular disease in patients with ankylosing spondylitis</td>
</tr>
<tr>
<td>A. Barcelos, R. Aguiar, C. Ambrósio (Portugal)</td>
<td>M.R.M.P. Soares, L. Bortolotto, F. Fernandes, M.M. Pinheiro, R.M. Ciconelli (Brazil)</td>
</tr>
<tr>
<td><strong>P25</strong></td>
<td><strong>P35</strong></td>
</tr>
<tr>
<td>Prevalence of cardiovascular risk factors in Filipinos with psoriatic arthritis</td>
<td>The performance of psoriatic arthritis classification criteria in psoriatic arthritis Turkish patients</td>
</tr>
<tr>
<td><strong>P26</strong></td>
<td><strong>P36</strong></td>
</tr>
<tr>
<td>Impaired heart rate recovery index in patients with ankylosing spondylitis</td>
<td>Anti-cyclic citrullinated peptide antibodies and shared-epitope prevalence in psoriatic arthritis</td>
</tr>
<tr>
<td>M.G. Kaya, M. Akpek, O. Dogdu, I. Ardic, O. Akgul, S. Ozgöçmen (Turkey)</td>
<td>A. Sellas, M. Barcelo, R. Farietta, B. Diez (Spain)</td>
</tr>
<tr>
<td><strong>P27</strong></td>
<td></td>
</tr>
<tr>
<td>How to deal with missing items in BASDAI and BASFI?</td>
<td></td>
</tr>
<tr>
<td>S. Ramiro, A. van Tubergen, D. van der Heijde, R. Landewé (The Netherlands)</td>
<td></td>
</tr>
</tbody>
</table>
Poster Viewing 2

**P37** Testicular Sertoli cell function in ankylosing spondylitis: The possible effect of TNF blockage

**P38** Secukinumab improves signs and symptoms of psoriatic arthritis: A 24-week, double-blind, trial

**P39** The frequency of non-radiographic axial spondyloarthritis in relation to symptom duration in patients referred because of chronic back pain
D. Poddubnyy, H. Brandt, J. Vahldiek, I. Spiller, I.H. Song, M. Rudwaleit, J. Sieper (Germany)

**P40** Prevalence and risk factors of anterior atlantoaxial subluxation in ankylosing spondylitis
J.S. Lee, S. Lee, K.B. Joo, Y.B. Kim, I.H. Sung, T.H. Kim (Korea)

**P41** Presence of peripheral arthritis prevents radiographic spinal damage progression in ankylosing spondylitis: Observation study of Korean Spondyloarthrophy Registry (OSKAR) cross-sectional and retrospective cohort study over 5 years

**P42** What do we miss? ASAS non-responders on anti-TNF therapy show improvement in physical function
S.F.E. Van Weely, J.C. Van Denderen, M.P.M. Steultjens, M.T. Nurmohamed, B.A.C. Dijkmans, J. Dekker, I.E. Van der Horst-Bruinsma (The Netherlands and UK)

**P43** Three easy to perform tests of physical functioning show improvement in ASAS20 non-responders after 3 months of anti-TNF therapy in ankylosing spondylitis
S.F.E. Van Weely, J. Dekker, M.P.M. Steultjens, J.C. Van Denderen, M.T. Nurmohamed, B.A.C. Dijkmans, I.E. Van der Horst-Bruinsma (The Netherlands and UK)

---

**Poster Viewing 2**

**P44** BASFI is a better indicator of low quality of life than BASDAI in ankylosing spondylitis – Results from the Scotland and Ireland registry for ankylosing spondylitis (SIRAS)
L.E. Morton, G.J. Macfarlane, G.T. Jones (UK)

**P45** Prevalence of inflammatory back pain in a UK primary care population
L.E. Hamilton, A.J. Macgregor, V. Warmington, E. Pinch, J.K. Gaffney (UK)

**P46** Disease patterns of psoriatic arthritis in a large series of Brazilian patients with spondyloarthritis

**P47** Epidemiologic profile of juvenile spondyloarthritis compared to adult-onset spondyloarthritis in a large Brazilian cohort

**P48** CASPAR and modified CASPAR criteria in early PsA patients
M. Zlatkovic-Švenda, D. Kerimovic-Morina, R. Stojanovic (Serbia)

**P49** Prevalence of SpA-related comorbidities, osteoporosis and fractures in ankylosing spondylitis
C. Stolwijk, A. Van Tubergen, J. Castillo-Ortiz, A. Boonen (The Netherlands)

**P50** The endogenous angiostatic mediators endostatin and thrombospondin-1 are increased in spondyloarthritis
L. Riente, I. Puxeddu, M. Tronchetti, A. Delle Sedie, S. Bombardieri, P. Migliorini (Italy)

**P51** Psychological status and associations with functional limitation in adolescents with ankylosing spondylitis
Y. Li, S.L. Zhang, J. Zhu, F. Huang (China)
P52  Effects of sleep quality to nocturnal pain in patients with ankylosing spondylitis  
S.L. Zhang, Y. Li, J. Zhu, F. Huang (China)

P53  Validity and reliability of the IPAQ and SQUASH to assess daily physical activity in patients with ankylosing spondylitis  
S. Arends, M. Hofman, Y.P.T. Kamsma, E. van der Veer, M.K. Leijisma, P.M. Houtman, C.G.M. Kallenber, A. Spoorenberg, E. Brouwer (The Netherlands)

P54  Validity and reliability of the Dutch translation of the psoriatic arthritis quality of life (PsAQoL) questionnaire  
F.R. Wink, S. Arends, S.P. McKenna, P.M. Houtman, E. Brouwer, A. Spoorenberg (The Netherlands and UK)

P55  NT-proBNP and inflammation in active ankylosing spondylitis receiving TNF blockers: Is there a link?  
J.C. Moraes, A.C.M. Ribeiro, C.G. Saad, A.C. Lianza, C.A. Silva, E. Bonfá (Brazil)

P56  High sensitive CRP levels correlate with BASDAI in axial SpA  
I.M. Hansen, Ø.T. Ferre, H. Nossent (Norway)

P57  Assessment of the T1W MRI should be included in the definition of a positive MRI of the sacroiliac joints in spondyloarthritis  

P58  C-reactive protein (CRP) polymorphisms and haplotypes influence serum CRP levels independent of disease activity (BASDAI) in ankylosing spondylitis  

P59  Epistasis between two HLA antigens defines a subset of individuals at a very high risk for ankylosing spondylitis  
F. van Gaalen, W. Verduijn, D. Roelen, S. Böhringer, T. Huizinga, D. van der Heijde, R. Toes (The Netherlands)

P60  Killer immunoglobulin receptors 3DL1 and 3DL2 binding tracks closely with surface expression of MHC class I free heavy chain and HLA B27 expressing abnormal peptides but does not distinguish B27 subtypes associated with ankylosing spondylitis  
N. Haroon, R.D. Inman (Canada)

P61  A genomewide association study of anterior uveitis  
T. Claushuis, A. Cortes, L.A. Bradbury, T.M. Martin, J.T. Rosenbaum, J.D. Reveille, J.J. Pointon, B.P. Wordsworth, D.M. Evans, P. Leo, P. Mukhopadhyay, M.A. Brown (Australia, USA and UK)

P62  Investigating the genetic association between ERAP1 and spondyloarthritis  
A. Kadi, B. Izac, R. Said-Nahal, A. Leboime, K. de Vlam, D. Elewaut, G. Chiocchia, M. Breban (France and Belgium)

P63  The non-synonymous polymorphism IL23R ARG381GLN is associated with ankylosis in spondyloarthritis  
A. Kadi, F. Costantino, B. Izac, R. Said-Nahal, A. Leboime, G. Chiocchia, M. Breban (France)

P64  How much does the SPARCC-score of the SI-joints change over a 3-month period in patients on non-biological treatment?  
R. van den Berg, M. de Hooge, V. Navarro-Compán, F. van Gaalen, M. Reijnierse, T. Huizinga, D. van der Heijde (The Netherlands)

P65  A SPARCC-score cut-off $\geq 3$ as best match for the ASAS definition of a positive MRI of the sacroiliac joints  
R. van den Berg, M. de Hooge, V. Navarro-Compán, M. Reijnierse, F. van Gaalen, T. Huizinga, D. van der Heijde (The Netherlands)

P66  Localisation of bone marrow edema in sacroiliac joints in spondyloarthritis patients: Does the site of lesions change over a 3-month period?  
M. de Hooge, R. van den Berg, M. Reijnierse, V. Navarro-Compán, F. van Gaalen, T. Huizinga, D. van der Heijde (The Netherlands)

P67  Assessing active inflammation in sacroiliac joints in spondyloarthritis patients: No added value of gadolinium compared to STIR sequence  
M. de Hooge, R. van den Berg, V. Navarro-Compán, F. van Gaalen, D. van der Heijde, T. Huizinga, M. Reijnierse (The Netherlands)
P68 New scoring system for radiographic sacroiliitis: A way to follow different structural changes
D. Poddubnyy, M. Rudwaleit, J. Sieper (Germany)

P69 No evidence for a role of the hypothesized sequence inflammation–fatty degeneration – New bone formation in patients with ankylosing spondylitis treated with anti-TNF agents over 5 years
X. Baraliakos, F. Heldmann, J. Listing, J. Calthoff, D. Pappas, J. Braun (Germany)

P70 Is there a role for hedgehog proteins in the development of syndesmophytes in patients with ankylosing spondylitis?
X. Baraliakos, F. Heldmann, J. Listing, M. van Werde, G. Ruiz-Heiland, A. Hueber, J. Braun, G. Schett (Germany)

P71 Concurrent sacroiliac joint and spinal inflammation on MRI in patients with non-radiographic axial spondyloarthritis
D. van der Heijde, J. Sieper, W. Maksymowych, M.A. Brown, S. Sarkar, A.L. Pangan (The Netherlands, Germany, Canada, Australia and USA)

Poster Viewing 3 is scheduled during the coffee break of 10.00–10.45 hrs on Saturday, October 6. The presenters of posters P72 through P106 are requested to be present at their posters.

P72 Inflammation and fatty degeneration are of similar importance for new bone formation in patients with ankylosing spondylitis treated with infliximab or other anti-TNF agents over 5 years

P73 Sclerostin does not predict radiographic progression in patients on anti-TNF therapy – New results from the European ankylosing spondylitis (AS) infliximab cohort (EASIC)

P74 Is enthesitis the primary immunopathological lesion in HLA-B27-associated experimental and human spondyloarthritis?
J. Paramarta, C. Van der Leij, I. Gofita, N. Yeremenko, M. Van de Sande, M. De Hair, P.P. Tak, J. Taurog, M. Maas, D. Baeten, L. Van Duivenvoorde (The Netherlands and USA)

P75 Low percentage of MRI changes in clinically suspected axial spondyloarthritis
M. Van der Weijden, S. Bruijnien, C.M.A. van der Bijl, B. Dijkmans, C. van der Laken, M. Nurmiomahed, I. van der Horst-Bruinsma (The Netherlands)

P76 Evolution of radiographic damage in ankylosing spondylitis over 12 years of follow-up
S. Ramiro, C. Stolwijk, A. van Tubergen, D. van der Heijde, R. Landewé (The Netherlands)

P77 Radiographic score for AS: MSASSS vs RASSS
S. Ramiro, C. Stolwijk, A. van Tubergen, D. van der Heijde, R. Landewé (The Netherlands)

P78 Superiority of optical coherence tomography over ultrasound for the assessment of nail disease in psoriasis and psoriatic arthritis

P79 MRI assessment of spinal involvement in PsA: Extent of disease relates to HLA-B27

P80 Comparison of conventional X-ray with CT using SASSS for ankylosing spondylitis patients
S.H. Lee, R. Song, S. Kim, Y.A. Lee, S.J. Hong, H.I. Yang (Korea)

P81 Spinal and sacroiliac inflammation as detected by magnetic resonance imaging in patients with ankylosing spondylitis, before and after 12 and 52 weeks therapy with non-steroidal anti-inflammatory drugs
E.Y. Tyukhova, A.V. Smirnov, O.A. Rumyaneva, A.G. Bochkova (Russia)
P82 MRI of the spine for detection of new bone formation in ankylosing spondylitis: Does it offer any advantages over radiography?
S.J. Pedersen, M. Ostergaard, R.G.W. Lambert, W.P. Maksymowych (Denmark and Canada)

P83 What constitutes the characteristic fat lesion on MRI of the sacroiliac joints in early spondyloarthritis?
U. Weber, S. Pedersen, V. Zubler, K. Rufibach, S. Chan, R. Lambert, M. Ostergaard, W.P. Maksymowych (Switzerland, Denmark and Canada)

P84 Two novel diagnostic biomarkers of cartilage degradation and connective tissue inflammation are predictive of disease progression in ankylosing spondylitis
A.C. Bay-Jensen, S. Wichuk, I. Byrjalsen, M.A. Karsdal, W.P. Maksymowych (Denmark and Canada)

P85 The SPARCC/SPARTAN (SPAR) reference imaging module for calibration of readers scoring with the MSASSS: Preliminary validation
W. Maksymowych, T. Learch, R. Lambert, M. Ward, N. Haroon, D. Salonen, R. Inman, M. Weisman (Canada and USA)

P86 Secukinumab reduces spinal inflammation as early as week 6, as detected by MRI – Results of a double-blind, phase II proof-of-concept study in patients with ankylosing spondylitis

P87 The beneficial role of SPECT/CT imaging over conventional bone scintigraphy in the diagnosis of early axial spondyloarthritis
H.Y. Lee, Y.K. Kim, K. Shin (Korea)

P88 Overexpression of toll-like receptor 2 on peripheral blood monocytes from patients with psoriatic arthritis (PsA)
S. Carrasco, F.S. Neves, M. Gambim, C.G. Saad, C. Gonçalves, P. Sampaio-Barros, C. Goldenstein-Schainberg (Brazil)

P89 Deletion of HLA-B27 T cells underlies the immunodominant response to influenza infection on class I MHC transgenic mice
A. Akram, N. Haroon, E. Gracey, A. Lin, K. Thickett, R.D. Inman (Canada)
Synovial fluid derived iNKT cells in chronic arthritides show an increased programmed death-1 expression and anergic phenotype
K. Venken, L. Melis, P. Jacques, L. Van Praet, F. Van den Bosch, D. Elewaut (Belgium)

Immunoglobulin subclass analysis in ankylosing spondylitis
M. Leger, A. Thavaneswaran, A. Anton, R. Inman (Canada)

Expression of HLA-B27 heavy chain forms in ankylosing spondylitis and HLA-B27 positive cell lines
O. Rysnik, K. McHugh, S. Kollnberger, J. Shaw, C. Renner, P. Bowness (UK and Switzerland)

Direct identification of endogenously processed HLA-B27-restricted epitopes from chlamydia trachomatis using LC-MS/MS
C. Alvarez-Navarro, J.J. Cragnolini, E. Barnea, A. Admon, J.A. López de Castro (Spain and Israel)

Microscopic gut inflammation in axial spondyloarthritis: A multiparametric predictive model
L. Van Praet, F. Van den Bosch, P. Jacques, Ph. Carron, H. Mielants, D. Elewaut (Belgium)

HLA-B27 misfolding and cellular stress influence the lifecycle of infecting salmonella? A potential mechanism for salmonella survival in reactive arthritis patients?

Microbes, the gut and ankylosing spondylitis
M.E. Costello, A. Cortes, P. Mukhopadhyay, P. Leo, M.A. Brown (Australia)

Metalloproteinase-3 (MMP-3) is a predictor for anti-TNFα response in patients with ankylosing spondylitis (AS)
V. Navarro-Compán, R. Ariza-Ariza, R. Mondéjar-García, V. Moreira-Navarrete, C. Leyva-Prado, C. González-Rodríguez, F. Navarro-Sarabia (Spain)
SO9  Efficacy and safety of adalimumab in peripheral spondylarthritis patients: Results from ABILITY-2
P. Mease, J. Sieper, F. Van den Bosch, P. Rahman, K. Obermeyer, A.L. Pangan (USA, Germany, Belgium and Canada)

SO10  Simultaneously modelling health impact, budget impact and cost-effectiveness in the context of population dynamics: The case of tumour necrosis factor-alpha antagonist for ankylosing spondylitis in the Dutch society
A. Tran-Duy, A. Boonen, M.A.F.J. van de Laar, J.L. Severens (The Netherlands)

SO11  MRI inflammation and its relation with measures of clinical disease activity and different treatment responses in patients with ankylosing spondylitis treated with a TNF inhibitor
P. Machado, R. Landewé, J. Braun, X. Baraliakos, K.G.A. Hermann, B. Hsu, D. Baker, D. van der Heijde (The Netherlands, Portugal and USA)

SO12  Secukinumab significantly improves ASAS20 responses versus placebo in moderate-to-severe ankylosing spondylitis patients

P107  Clinical efficacy and safety of infliximab–results after a decade of continuous treatment in ankylosing spondylitis
X. Baraliakos, J. Listing, C. Fritz, H. Haibel, J. Sieper, J. Braun (Germany)

P108  Long-term outcome of patients with active ankylosing spondylitis with etanercept – Sustained efficacy and safety after 7 years
X. Baraliakos, H. Haibel, C. Fritz, J. Listing, F. Heldmann, J. Braun, J. Sieper (Germany)

P109  Disease burden is comparable in non-radiographic axial spondyloarthritis and ankloysing spondylitis patients: Treatment implications
J. Sieper, D. van der Heijde, D. Elewaut, A.L. Pangan, J. Anderson (Germany, The Netherlands, Belgium and USA)

P110  Sustained efficacy of adalimumab in non-radiographic axial spondylarthritis: Week 68 results from ABILITY 1
J. Sieper, D. van der Heijde, M. Dougados, F. Van den Bosch, P. Goupille, S. Sarkar, A.L. Pangan (Germany, The Netherlands, Belgium, France and USA)

P111  Increase in bone mineral density and decrease in WNT3A, OPG, CTX-I and osteocalcin in ankylosing spondylitis treated with alendronate
H. Forsblad-d’Elia, M. Nurkkala, K. Zetterberg, E. Klingberg, H. Carlsten (Sweden)

P112  Double-blind, placebo-controlled trial of efficacy and safety of infliximab+ naproxen vs naproxen in patients with early, active axial spondyloarthritis treated with submaximal NSAIDs: INFAST part I
J. Sieper, J. Lenaerts, J. Wollenhaupt, V.I. Mazurov, L. Myasoutova, S. Park, Y. Song, R. Yao, D. Chitkara, N. Vastesaeger (Germany, Belgium, Russia, South Korea and USA)

P113  A randomized, open-label study to explore whether partial remission can be maintained with naproxen or no treatment in patients with early, active axial spondyloarthritis: INFAST part II
J. Sieper, J. Lenaerts, J. Wollenhaupt, V.I. Mazurov, L. Myasoutova, S. Park, Y. Song, R. Yao, D. Chitkara, N. Vastesaeger (Germany, Belgium, Russia, South Korea and USA)

P114  Efficacy and safety of adalimumab for the treatment of peripheral arthritis in spondylarthritis patients without ankylosing spondylitis or psoriatic arthritis

P115  Adalimumab significantly reduces recurrence rate of anterior uveitis in patients with ankylosing spondylitis
J.C. Van Denderen, I.M. Visman, M.T. Nurrmohamed, M.S.A. Suttrop-Schulten, I.E. Van der Horst-Bruinsma (The Netherlands)

P116  European ankylosing spondylitis (AS) infliximab cohort (EASIC) long-term extension: Efficacy and safety of infliximab over a time period of more than 7 years in patients with AS

P117  Efficacy and safety of adalimumab in Chinese adults with active ankylosing spondylitis
P118 Use of DMARDs and anti-TNFs in treatment of ankylosing spondylitis at a university hospital
H. Relas, H. Kautiainen, K. Puolakka, M. Leirisalo-Repo (Finland)

P119 Predictive factors of response at 12 weeks in patients with ankylosing spondylitis starting biological therapies - Results from the Portuguese register - Reuma.pt

P120 Thalidomide significantly improved patient’s sleep, anxiety, depression status in refractory ankylosing spondylitis
S.L. Zhang, Y. Li, J. Zhu, F. Huang (China)

P121 Dose reduction of TNF-α blocking agents in ankylosing spondylitis patients with stable low disease activity
S. Arends, E. van der Veer, F.B.S. Kamps, K.M.E. Pool, E. Brouwer, A. Spoorenberg (The Netherlands)

P122 Treatment in mono-/oligo- and polyarthritic patients: A 5 year study on the Swedish early psoriatic arthritis cohort (SWEPSA)
U. Lindqvist, T. Husmark, G.M. Aleniu, P.T. Larsson, A. Teleman, M. Geijer, E. Theander (Sweden)

P123 Efficacy and safety of low-dose infliximab in ankylosing spondylitis
C. Schaufelberger, B. Mörck, L. Jacobsson (Sweden)

P124 Effect of long-term TNF blockage on lipid profile in ankylosing spondylitis patients
J.C. Moraes, F.H.C. Souza, A.C.M. Ribeiro, C.G.S. Saad, A.L. Calich, C.G. Schainberg, C.A. Silva, E. Bonfa (Brazil)

P125 Anti-tumor necrosis factor agents may prevent cartilage loss of hip in patients with ankylosing spondylitis
S.H. Lee, R. Song, Y.A. Lee, S.J. Hong, H.I. Yang (Korea)

P126 The efficacy of TNF blockade with MTX therapy in patients with TNF blockade resistance
S.H. Lee, R. Song, S. Kim, Y.A. Lee, S.J. Hong, H.I. Yang (Korea)

P127 Sarcopenia reversal in ankylosing spondylitis (AS) under anti-TNF therapy: A 24-month longitudinal analysis
C.G.S Saad, M.A. Barros, L. Takayama, J.C.B. Moraes, A.C.M. Ribeiro, E. Bonfa, R.M.R. Pereira (Brazil)

P128 Tapering infliximab in ankylosing spondylitis: Can we reduce costs?
P. Ávila-Ribeiro, E. Vieira-Sousa, H. Canhão, J.E. Fonseca (Portugal)

P129 Anti-TNF therapy slows radiographic progression of ankylosing spondylitis and opposes the effects of smoking and inflammation
N. Haroon, R.D. Inman, T. Learch, M. Weisman, M.M. Ward, J.D. Reveille, L.S. Gensler (Canada and USA)
General Information

Dates
Thursday, October 4 - Saturday, October 6, 2012

Venue
‘Het Pand’, Onderbergen 1, 9000 Gent
Direct numbers during the Congress:
Phone: +32 (0)9 264 83 05, fax: +32 (0)9 264 83 96
‘Het Pand’ is a medieval convent located in the heart of the city, owned by the University of Gent and used as an exclusive Congress Centre.
‘Het Pand’ is located next to the St Michiels Church, within walking distance from the hotels. The short walk to the congress venue will give the participants a general impression of Gent’s architectural splendour (St Bavo’s Cathedral, St Nicholas’ Church, Town Hall, Castle of the Counts).

Parking Facilities
The centre of the city is largely car free.
Hotels can be reached and participants are advised to park their cars at the car park ‘Sint Michiels’ which is located opposite ‘Het Pand’. In order to reach this parking, participants are advised to enter the city from the southern part of the ring road and to follow the signs P7 “Parking Sint Michiels”.

Language
The official congress language is English.

Liability
Neither the organisers nor Medicongress accept liability for damages and/or losses of any kind which may be incurred by Congress participants during the Congress. Participants are advised to take out insurance against loss, accidents or damage which could be incurred during the Congress.

Organisation and Administration
MEDICONGRESS
Kloosterstraat 5
B-9960 Assenede, Belgium
Phone: +32 (0)9 344 39 59
Fax: +32 (0)9 344 40 10
E-mail: spondylo@medicongress.com

Programme developed in collaboration with Wonder Reizen, Lic. A 5603

Social Programme

Opening Reception and Walking Dinner on Thursday, October 4
This Opening Reception and Walking Dinner is included in the registration fee, but pre-registration is mandatory.
The Opening Reception and Walking Dinner starts at 19.00 hrs and takes place in the Kapittelzaal [ground floor].

Gala Dinner on Friday, October 5
The Gala Dinner takes place at the Flemish Opera House, a beautiful theatre that dates back to 1840, with three magnificent ‘salons’ [Foyer, Redoute hall and Lully hall] forming an impressive 90 metre long ‘enfilade’.

Pre-registration and separate payment is mandatory. A limited number of tickets are available and can be purchased at the registration desk at €50,00.

Farewell Reception and Walking Dinner on Saturday, October 6
This Farewell Reception and Walking Dinner is included in the registration fee, but pre-registration is mandatory.
The Farewell Reception and Walking Dinner starts at 17.15 hrs and takes place in the Kapittelzaal [ground floor].
Registration

As of October 1, 2012

Participant € 700,00
Non-MD € 550,00
Gala Dinner at the Opera House € 50,00*

*If seats are available

- The registration fee includes access to all lectures, workshops, coffee breaks, lunches and Opening Reception and Farewell Walking Dinner as indicated in the programme. Participants also have free access to the exhibition.

- Separate registration for the Gala Dinner at the Opera House is mandatory.

Payment
Payment is to be made by credit card. All major credit cards are accepted.

Cancellations
Cancellations received no later than August 31, 2012, entitle registered persons to a 50% refund. Name substitutions are possible at an extra charge of € 100,00.